Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Plevritis and colleagues1 used a computer model to evaluate the cost-effectiveness of using breast magnetic resonance imaging (MRI) to screen carriers of BRCA1/2 mutations. Based on their assumptions, the authors concluded that the most cost-effective strategy is annual breast MRI for BRCA1/2 carriers from age 35 to 54 years.
Crystal P. Cost-effectiveness of Breast Magnetic Resonance Imaging to Screen. JAMA. 2006;296(22):2681-2682. doi:10.1001/jama.296.22.2681-b